Pharma News

The latest developments from pharmaceutical and biopharmaceutical companies, both innovator and generic-drug companies, and leading regulatory news.

Bristol-Myers Squibb (BMS) has agreed to acquire MyoKardia, a Brisbane, California-based clinical-stage biopharmaceutical company focused on cardiovascular diseases, for $13.1 billion. MyoKardia’s lead drug candidate is mavacamten, in Phase III...

Sanofi has completed its $3.68-billion acquisition of Principia Biopharma, a South San Francisco, California-based clinical-stage biopharmaceutical company focused on immune-mediated diseases. Sanofi had announced the acquisition in late August...

Sun Pharma, a wholly owned subsidiary of Sun Pharmaceutical Industries, a Mumbai, India-based pharmaceutical company, is the latest company recalling a metformin extended-release product due to a nitrosamine impurity, N-ntrosodimethylamine (NDMA),...

The latest on manufacturing and potential treatments for COVID-19 with news from J&J, Inovio, Novavax, Endo International, and the Serum Institute of India. J&J Reports Positive Phase I/IIa Results for its COVID-19 Vaccine Johnson &...

Bayer has announced additional cost-cutting measures of EUR 1.5 billion ($1.76 billion) by 2024 to address headwinds encountered in its crop sciences and pharmaceutical businesses that were attenuated by the COVID-19 pandemic.The additional...

Belén Garijo, currently Deputy Chief Executive Officer (CEO), CEO Healthcare, and Vice Chair of the Executive Board of Merck KGaA, has been named as the company’s new Chair of the Executive Board and CEO, effective May 1, 2021. Stefan Oschmann,...

Roche has acquired Inflazome, a Dublin, Ireland-based company developing inflammasome inhibitors for treating chronic inflammatory diseases, for EUR 380 million ($443 million) with Inflazome shareholders also eligible to receive additional...

Pfizer has entered into a manufacturing agreement with Vivet Therapeutics, a Paris-based gene-therapy company developing treatments for inherited liver disorders, under which Pfizer will provide clinical supply for a Phase I/II clinical trial...

Valneva, a Saint-Herblain, France-headquartered vaccine company, has entered into an agreement with the UK government to provide up to 190 million doses of its COVID-19 vaccine candidate, VLA2001, over a five-year period, in a deal worth up to $1.6...